Adjuvant Therapy for Hepatocellular Carcinoma: Standard of Care?

Nov 17 2024
Convention Center: Room 25 A
12:45 PM - 1:30 PM
Ticketed Event

World Class Speakers

Robin Kate Kelley, MD
Discussion Leader

Robin Kate Kelley, MD

University of California, San Francisco
GS
Discussion Leader

Gonzalo Sapisochin

Description

Faculty discuss findings from IMbrave-050 and EMERALD-1 clinical trials and ongoing studies (CheckMate 9DX, KEYNOTE-937, EMERALD-2, et al) that inform the utilization of immunotherapy in the adjuvant setting after surgery or locoregional therapy (LRT).

Journey Maps

Objectives

  • Describe how to critically evaluate data from trials with results related to the benefit of checkpoint inhibitor therapy after surgery or LRT.
  • Discuss pros and cons of adjuvant versus on-demand utilization of checkpoint inhibitor therapy in post-LRT or surgery settings.
  • Identify knowledge gaps for future studies in this space.